

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

OSI PHARMACEUTICALS, LLC
and GENENTECH, INC.,

Petitioner,

v.

ARCH DEVELOPMENT CORP. and
DANA-FARBER CANCER INSTITUTE, INC.,

Patent Owner.

Case IPR2016-01034
Patent 7,838,512 B1

Before LORA M. GREEN, TINA E. HULSE, and
ROBERT A. POLLOCK, *Administrative Patent Judges*.

POLLOCK, *Administrative Patent Judge*.

FINAL WRITTEN DECISION
Claims 1–3, 5, and 6 Shown to Be Unpatentable
35 U.S.C. § 318(a); 37 C.F.R. § 42.73

I. INTRODUCTION

This is a Final Written Decision in an *inter partes* review challenging the patentability of claims 1–3, 5, and 6 (collectively, “the challenged claims”) of U.S. Patent No. 7,838,512 B1 (Ex. 1001, “the ’512 patent”). We have jurisdiction under 35 U.S.C. § 6. For the reasons that follow, we determine that Petitioner has shown, by a preponderance of the evidence, that claims 1–3, 5, and 6 of the ’512 patent are unpatentable.

A. *Procedural History*

OSI Pharmaceuticals, LLC and Genentech, Inc., (“Petitioner”)¹ filed a Petition requesting an *inter partes* review of claims 1–3, 5, and 6 of the ’512 patent. Paper 3 (“Pet.”). Arch Development Corp. and Dana-Farber Cancer Center Institute, Inc. (“Patent Owner”) filed a Preliminary Response to the Petition. Paper 8 (“Prelim. Resp.”). Based on these submissions, we instituted an *inter partes* review of claims 1–3, 5, and 6 on the following grounds of unpatentability alleged in the Petition. Paper 9 (“Inst. Dec.”).

¹ Petitioner further identifies Astellas US LLC, Astellas US Holding, Inc., Astellas Pharma Inc., and Roche Holdings, Inc. as real parties in interest.
Pet. 4

Ground	References	Basis
II	Honma ² , in view of the knowledge of a person of ordinary skill in the art (“POSA”), Honma 1992, ³ and McGahon ⁴	§ 103
IV	Akinaga, ⁵ in view of the knowledge of a POSA, Seynaeve, ⁶ Friedman, ⁷ and Tam ⁸	§ 103

After institution of trial, Patent Owner filed a Patent Owner Response (Paper 16, “PO Resp.”), to which Petitioner filed a Reply (Paper 34, “Reply”).

In support of its challenges, Petitioner relies on the Declaration of Alan Eastman, Ph.D. (Ex. 1002). Patent Owner relies on the Declaration of first named inventor, Donald W. Kufe, M.D. (Ex. 2011).

² Yoshio Honma et al., *Induction of Erythroid Differentiation of K562 Human Leukemic Cells by Herbimycin A, an Inhibitor of Tyrosine Kinase Activity*, 49 *CANCER RES.* 331–34 (1989). Ex. 1003.

³ Yoshio Honma et al., *Herbimycin A, an Inhibitor of Tyrosine Kinase, Prolongs Survival of Mice Inoculated with Myeloid Leukemia C1 Cells with High Expression of v-abl Tyrosine Kinase*, 52 *CANCER RES.* 4017–20 (1992). Ex. 1022.

⁴ Anne McGahon et al., *BCR-ABL Maintains Resistance of Chronic Myelogenous Leukemia Cells to Apoptotic Cell Death*, 83 *BLOOD* 1179–87 (1994). Ex. 1029.

⁵ Shiro Akinaga et al., *Enhancement of Antitumor Activity of Mitomycin C In Vitro and In Vivo by UNC-01, a Selective Inhibitor of Protein Kinase C*, 32 *CANCER CHEMOTHERAPY AND PHARMACOLOGY* 183–89 (1993). Ex. 1004.

⁶ Caroline M. Seynaeve et al., *Cell Cycle Arrest and Growth Inhibition by the Protein Kinase Antagonist UCN-01 in Human Breast Carcinoma Cells*, 53 *CANCER RES.* 2081–86 (1993). Ex. 1014.

⁷ BethAnn Friedman et al., *Regulation of the Epidermal Growth Factor Receptor by Growth-Modulating Agents: Effects of Staurosporine, a Protein Kinase Inhibitor*, 50 *CANCER RES.* 533–38 (1990). Ex. 1031.

⁸ Sun W. Tam and Robert Schlegel, *Staurosporine Overrides Checkpoints for Mitotic Onset in BHK Cells*, 3 *CELL GROWTH & DIFFERENTIATION* 811–17 (1992). Ex. 1012.

Patent Owner filed a Motion to Exclude. Paper 37. Petitioner filed an Opposition (Paper 38), and Patent Owner filed a Reply (Paper 40). An oral hearing was held on June 20, 2017. A transcript of the hearing has been entered into the record. Paper 42 (“Tr.”).

B. Related Proceedings

The ’512 Patent is at issue in *Arch Development Corp. v. Genentech, Inc.*, No. 1:15-cv-6597 (N.D. Ill.), which is currently stayed. Pet. 4; Paper 6; Paper 20, 1.

C. The ’512 Patent and Relevant Background

The ’512 patent is directed to the use of DNA damaging agents in combination with tyrosine kinase inhibitors (TKIs) to enhance cancer cell death. *See generally* Ex. 1001, Title, Abstract, 4:12–40, 5:28–38.

According to Petitioner’s expert, Dr. Eastman, tyrosine kinases are enzymes that catalyze the phosphorylation of a substrate protein by attaching a phosphoryl group to a tyrosine amino acid residue on the substrate.

Ex. 1002 ¶ 31. Tyrosine kinases were known to be involved in cell signaling pathways that control cell growth, differentiation, and cell death. Pet. 7 (citing Ex. 1002 ¶¶ 31–38). Elevated tyrosine kinase activity has also been associated with cancers because it can promote abnormal cell proliferation. *Id.* (citing Ex. 1002 ¶ 37).

According to the Specification, the treatment of cancer cells with ionizing radiation or chemotherapeutic agents such as the DNA alkylating agent, mitomycin C, results in DNA damage. Ex. 1001, 1:32–35, 3:51–65, 4:41–54. “The cellular response to DNA damage includes activation of DNA repair, cell cycle arrest, and lethality (Hall, 1988).” *Id.* at 1:32–35. As explained by Petitioner:

By 1994, it was well known that the cell cycle involves progression through four phases: G1 (growth phase); S (copying of DNA); G2 (rapid growth in preparation for mitosis/cell division); M (mitosis/cell division). (Eastman Decl. ¶¶40-41 (Ex. 1002).) The cell cycle can arrest in G1, S and G2 to allow cells with damaged DNA to repair their DNA. (*Id.* ¶42.) In part, these “checkpoints” are regulated by tyrosine kinases. (*Id.* ¶44.) Cells with damaged DNA that advance to the M phase, however, cannot properly divide and instead die. (*Id.*)

Pet. 8. Consistent with this summary, the Specification points to prior art showing that environmental conditions following exposure to DNA damaging agents can influence cell survival. Ex. 1001, 1:38–55, 2:50–63. For example,

cell survival can be increased if the cells are arrested in the cell cycle for a protracted period of time following radiation exposure, allowing repair of DNA damage. (Hall, 1988). Thus [potentially lethal damage] is repaired and the fraction of cells surviving a given dose of x-rays is increased if . . . cells do not have to undergo mitosis while their chromosomes are damaged.”

Id. at 2:56–63. The Specification further states that “available evidence suggests that G₂ arrest is necessary for repair of DNA damage before entry into mitosis.” *Id.* at 1:37–44; *see also id.* at 3:43–46. In particular, “[c]ells that are irradiated or treated with DNA damaging agents halt in the cell cycle at G₂, so that an inventory of chromosome damage can be taken and repair initiated and completed before mitosis is initiated.” *Id.* at 3:3–7. “By preventing delays in G₂, cells will enter mitosis before the DNA is repaired and therefore the daughter cells will likely die.” *Id.* at 3:46–48.

Recognizing that DNA damaging agents result in the activation of p56/p53^{lyn} tyrosine kinase, a protein implicated in cell cycle control,⁹ the

⁹ Example 1 of the Specification discloses that the DNA damaging agent mitomycin C activates (via autophosphorylation) the tyrosine kinase

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.